BillionToOne
Researchers confirmed prior data showing 100 percent accuracy for the test, but in a clinical-use population where they also observed growing adoption by physicians.
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Labcorp, Hologic, CareDx, More
Highlights from the first day included updates from several firms about their China businesses and M&A strategies.
BillionToOne Raises $130M in Series D Financing Round
The Menlo Park, California-based company will use the funds to expand and scale its prenatal and oncology testing businesses.
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
Premium
The Northstar Select comprehensive genomic profiling test uses BillionToOne's proprietary Quantitative Counting Template technology for solid tumors.